eftilagimod alfa

Sponsor Immutep LTD · listed as IMMP

READOUT Phase 3 Confidence: medium Source: clinicaltrials

eftilagimod alfa is a clinical-stage drug asset sponsored by Immutep LTD, listed as IMMP. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2027 (month precision, medium confidence), tied to trial NCT06726265. The asset is in Phase 3 and currently active not recruiting, studied in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC).

Next catalyst

Event typeREADOUT

Expected date2027-06-30

As disclosedJun 2027

Date precisionmonth

Confidencemedium

Verify at source →

Trial & sponsor

Trial (NCT)NCT06726265

PhasePHASE3

StatusACTIVE_NOT_RECRUITING

Lead sponsorImmutep S.A.S.

Listed asIMMP

Condition(s)Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 → More IMMP catalysts